A Phase 1 interventional study of Axitinib (AG-013736) in Carcinoma, sponsored by Pfizer. Completed at 1 site in Japan. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2012-05-23.
Sponsored by Pfizer · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Carcinoma by Pfizer — 6 open to participants now, 6 under way, 2 of them phase 3. Carcinoma · Pfizer.
Among the 27 studies in Carcinoma by Pfizer, this one is the 23rd largest by enrollment of the 24 interventional ones that give a count, is one of 2 that started in 2007, is one of 9 in phase 1, and was the 8th registered.
736 studies on the registry are indexed under Carcinoma; 149 are open to participants now.
Browse Carcinoma studies →6 of the 27 studies in Carcinoma by Pfizer are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in United States
Ages 18+
Pfizer · Sites in United States, Australia, China and 8 more countries
Ages 18+
Pfizer · Sites in United States, Australia, China and 3 more countries
Ages 18+
Pfizer · Sites in United States, Argentina, Australia and 17 more countries
Ages 18+
Pfizer · Sites in United States, Argentina, Australia and 28 more countries
Ages 18+
By country, each count listing its studies:
Of the 115 Carcinoma studies recruiting now, 92 (80%) set no upper age limit and 14 (12%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.
This study: 20 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 10 · Phase 3 3 · Phase 4 2
First in 2001; this study’s year is marked. 2 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12 is below the median of 49 across 571 interventional studies indexed under Carcinoma.
Median enrollment 98 across the 24 interventional studies, 684 across the 3 observational. Of the 21 that completed or were terminated, 12 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
1 of the studies in Carcinoma by Pfizer that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07227415PfizerSymbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer | 2027-11-02 |
Add it to your calendar (.ics) → With an account.
Among the 27 studies in Carcinoma by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the clinically recommended dose of AG-013736 (Axitinib) in Japanese patients by reviewing the safety of AG-013736 (Axitinib) following single and multiple dosing.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Axitinib (AG-013736)
AG-013736 5mg twice daily \[BID\]
Number of Participants With Adverse Events
Number of participants with any adverse events, adverse events graded as Common Terminology Criteria for Adverse Events Version 3.0 (CTCAE) Grade 3 or higher, serious adverse events, and adverse events resulted in discontinuation.
Time frame: Up to 795 days of treatment plus 28-days follow-up
Maximum Observed Plasma Concentration (Cmax): Single Dose
Time frame: Single dose: predose, 0.5, 1, 2, 4, 6, 8, 12, 24, and 32 hours postdose
Time to Reach Maximum Observed Plasma Concentration (Tmax): Single Dose
Time frame: Single dose: predose, 0.5, 1, 2, 4, 6, 8, 12, 24, and 32 hours postdose
Area Under The Plasma Concentration-Time Curve From Time Zero to Time Infinity (AUCinf): Single Dose
AUCinf is obtained from AUC (0 - t) plus AUC (t - infinity).
Time frame: Single dose: predose, 0.5, 1, 2, 4, 6, 8, 12, 24, and 32 hours postdose
Terminal Phase Plasma Half-Life (t1/2): Single Dose
t1/2 is the time measured for the plasma concentration to decrease by one half.
Time frame: Single dose: predose, 0.5, 1, 2, 4, 6, 8, 12, 24, and 32 hours postdose
Maximum Observed Plasma Concentration (Cmax): Multiple Dose
Time frame: Multiple dose Cycle 1 Day 1 and 15: predose, 0.5, 1, 2, 4, 8 and 12 hours postdose
Time to Reach Maximum Observed Plasma Concentration (Tmax): Multiple Dose
Time frame: Multiple dose Cycle 1 Day 1 and 15: predose, 0.5, 1, 2, 4, 8 and 12 hours postdose
Area Under The Plasma Concentration-Time Curve Over Dosing Interval Tau (AUCtau): Multiple Dose
Dosing Interval was 12 hours in this study.
Time frame: Multiple dose Cycle 1 Day 1 and 15: predose, 0.5, 1, 2, 4, 8 and 12 hours postdose
Accumulation Ratio for Cmax (Rac Cmax) and Accumulation Ratio for AUCtau (Rac AUCtau): Multiple Dose
Rac Cmax is obtained from Cmax (Cycle 1, Day 15) divided by Cmax (Cycle 1, Day 1) Rac AUCtau is obtained from AUCtau (Cycle 1, Day 15) divided by AUCtau (Cycle 1, Day 1)
Time frame: Multiple dose Cycle 1 Day 1 and 15: predose, 0.5, 1, 2, 4, 8 and 12 hours postdose
Percent Change From Baseline in Soluble Vascular Endothelial Growth Factor Receptor 2 and 3 (s-VEGFR2 and s-VEGFR3), Vascular Endothelial Growth Factor (VEGF), Soluble Stem Cell Factor Receptor (s-KIT)
Percent change from baseline is obtained from (observed value minus baseline value) divided by baseline value multiplied by 100 in each parameter, i.e., VEGFR2, s-VEGFR3, s-KIT, and VEGF.
Time frame: Prior to the initial dose (baseline), Day 1 of Cycle 2 and at the discontinuation
The Numbers of Participants With Best Overall Response of Complete Response (CR), Partial Response (PR), Stable Disease (SD), and Progression of Disease (PD) According to the Response Evaluation Criteria in Solid Tumors (RECIST Version 1.0)
CR was defined as the disappearance of all target and nontarget lesions and no appearance of new lesions. PR was defined as at least a 30% decrease in the sum of the longest diameters (SLD) of the targeted lesions. CR and PR had to be documented on 2 occasions separated by at least 4 weeks. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify as PD being demonstrated during the first 8 weeks. PD was defined as at least a 20% increase in the SLD of target lesions compared to the smallest SLD since the study treatment started.
Time frame: Up to 795 days
| Milestone | AG-013736 |
|---|---|
| Started | 12 |
| Completed | 0 |
| Not completed | 12 |
| Withdrew: Adverse event | 1 |
| Withdrew: Lack of efficacy | 11 |
Number of participants with any adverse events, adverse events graded as Common Terminology Criteria for Adverse Events Version 3.0 (CTCAE) Grade 3 or higher, serious adverse events, and adverse events resulted in discontinuation.
| participants | AG-013736 |
|---|---|
| Any adverse events | 12 |
| Any serious adverse events | 5 |
| Any Grade-3 or -4 adverse events | 7 |
| Any Grade-5 adverse events (= death) | 0 |
| Discontinuation due to adverse events | 1 |
| ng/mL | AG-013736 |
|---|---|
| Maximum Observed Plasma Concentration (Cmax): Single Dose | 29.97 ± 9.97 |
| hours | AG-013736 |
|---|---|
| Time to Reach Maximum Observed Plasma Concentration (Tmax): Single Dose | 4 (2 to 6) |
AUCinf is obtained from AUC (0 - t) plus AUC (t - infinity).
| ng*hr/mL | AG-013736 |
|---|---|
| Area Under The Plasma Concentration-Time Curve From Time Zero to Time Infinity (AUCinf): Single Dose | 210.3 ± 146.5 |
t1/2 is the time measured for the plasma concentration to decrease by one half.
| hours | AG-013736 |
|---|---|
| Terminal Phase Plasma Half-Life (t1/2): Single Dose | 4.8 ± 1.146 |
| ng/mL | AG-013736 |
|---|---|
| Cycle 1 Day 1 (n=12) | 23.85 ± 10.94 |
| Cycle 1 Day 15 (n=11) | 32.14 ± 18.04 |
| hours | AG-013736 |
|---|---|
| Cycle 1 Day 1 (n=12) | 3 (2 to 4) |
| Cycle 1 Day 15 (n=11) | 4 (1 to 4) |
Dosing Interval was 12 hours in this study.
| ng*h/mL | AG-013736 |
|---|---|
| Cycle 1 Day 1 (n=12) | 137.3 ± 84.3 |
| Cycle 1 Day 15 (n=11) | 187.8 ± 125.3 |
Rac Cmax is obtained from Cmax (Cycle 1, Day 15) divided by Cmax (Cycle 1, Day 1) Rac AUCtau is obtained from AUCtau (Cycle 1, Day 15) divided by AUCtau (Cycle 1, Day 1)
| ratio | AG-013736 |
|---|---|
| Rac Cmax (n=11) | 1.449 ± 0.471 |
| Rac AUCtau (n=11) | 1.541 ± 0.489 |
Percent change from baseline is obtained from (observed value minus baseline value) divided by baseline value multiplied by 100 in each parameter, i.e., VEGFR2, s-VEGFR3, s-KIT, and VEGF.
| percent change | AG-013736 |
|---|---|
| s-VEGFR2: Cycle 2 Day 1 (n=12) | -41.73 (-53.2 to -10.1) |
| s-VEGFR2: At discontinuation (n=11) | -40.57 (-53.0 to -8.4) |
| s-VEGFR3: Cycle 2 Day 1 (n=12) | -52.50 (-93.7 to -15.6) |
| s-VEGFR3: At discontinuation (n=11) | -65.48 (-81.2 to 39.4) |
| s-KIT: Cycle 2 Day 1 (n=12) | -0.26 (-23.8 to 33.5) |
| s-KIT: At discontinuation (n=11) | 4.66 (-31.2 to 12.9) |
| VEGF: Cycle 2 Day 1 (n=12) | 266.92 (14.9 to 1030.4) |
| VEGF: At discontinuation (n=11) | 43.48 (-15.5 to 423.1) |
CR was defined as the disappearance of all target and nontarget lesions and no appearance of new lesions. PR was defined as at least a 30% decrease in the sum of the longest diameters (SLD) of the targeted lesions. CR and PR had to be documented on 2 occasions separated by at least 4 weeks. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify as PD being demonstrated during the first 8 weeks. PD was defined as at least a 20% increase in the SLD of target lesions compared to the smallest SLD since the study treatment started.
| participants | AG-013736 |
|---|---|
| CR | 0 |
| PR | 0 |
| SD | 10 |
| PD | 2 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AG-013736 | — | 5/12 (41.7%) | 12/12 (100%) |
| Event | AG-013736 |
|---|---|
| Intestinal obstructionGastrointestinal disorders | 2/12 |
| PyrexiaGeneral disorders | 2/12 |
| Cardiac tamponadeCardiac disorders | 1/12 |
| Liver abscessInfections and infestations | 1/12 |
| Event | AG-013736 |
|---|---|
| Decreased appetiteMetabolism and nutrition disorders | 11/12 |
| DiarrhoeaGastrointestinal disorders | 10/12 |
| FatigueGeneral disorders | 10/12 |
| StomatitisGastrointestinal disorders | 9/12 |
| Blood thyroid stimulating hormone increasedInvestigations | 9/12 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 8/12 |
| Blood urine presentInvestigations | 7/12 |
| DysphoniaRespiratory, thoracic and mediastinal disorders | 7/12 |
| ConstipationGastrointestinal disorders | 6/12 |
| Aspartate aminotransferase increasedInvestigations | 6/12 |
| Age Continuous(years) | AG-013736 |
|---|---|
| Mean | 60.2 ± 13.1 |
| Sex: Female, Male(Participants) | AG-013736 |
|---|---|
| Female | 5 |
| Male | 7 |
The record gives a start of Feb 2007, a primary completion of Aug 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2012, 2 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Axitinib